慢性淋巴细胞白血病中克隆演化导致依鲁替尼耐药
在研究者发起的2期试验中,84例可评估的慢性淋巴细胞白血病(CLL)患者接受单药依鲁替尼治疗,中位随访34个月,15例(17.9%)进展。组织学转化限于前15个月,而CLL进展较晚;进展时9例(10.7%)检出BTK(Cys481)和/或PLCG2突变,高灵敏度检测可在临床进展前长达15个月检出突变。
要点
- 单药依鲁替尼治疗CLL,中位随访34个月,84例可评估患者中15例(17.9%)进展。
- 组织学转化5例(6.0%)限于前15个月;CLL进展10例(11.9%)中位38个月诊断。
- 进展时9例(10.7%)检出BTK Cys481和/或PLCG2突变,高灵敏度检测可提前最多15个月发现。
核心结论
- 接受单药依鲁替尼治疗的CLL患者中,疾病进展可表现为组织学转化或CLL进展,后者常伴BTK和/或PLCG2突变,且耐药疾病存在亚克隆异质性。
研究设计与样本
- 研究者发起的2期试验(NCT01500733),CLL患者接受单药依鲁替尼治疗,84例可评估,中位随访34个月。
主要发现
- 84例可评估患者中15例(17.9%)进展;组织学转化5例(6.0%),限于用药前15个月;CLL进展10例(11.9%),中位诊断时间38个月。
- 进展时9例(10.7%)检出BTK(Cys481)和/或PLCG2(自抑制域内)突变,其中CLL进展者10例中8例,幼淋巴细胞转化者1例。
- 高灵敏度检测(检测限约1/1000细胞)可在临床进展表现前最多15个月检出突变(范围2.9-15.4个月)。
- 5例(6.0%)出现携带不同突变的多个亚克隆独立发生,导致耐药疾病的亚克隆异质性。
- 研究入组时复发/难治、TP53异常、晚期Rai分期和高β-2微球蛋白均与较差的无进展生存期独立相关(所有检验P < .05)。
临床怎么用
- CLL进展的患者继续依鲁替尼治疗最多3个月以无缝过渡至替代靶向药物,自进展起中位生存19.8个月。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Disease progression in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib has been attributed to histologic transformation or acquired mutations in BTK and PLCG2. The rate of resistance and clonal composition of PD are incompletely characterized. We report on CLL patients treated with single-agent ibrutinib on an investigator-initiated phase 2 trial. With median follow-up of 34 months, 15 of 84 evaluable patients (17.9%) progressed. Relapsed/refractory disease at study entry, TP53 aberration, advanced Rai stage, and high β-2 microglobulin were independently associated with inferior progression-free survival (P < .05 for all tests). Histologic transformation occurred in 5 patients (6.0%) and was limited to the first 15 months on ibrutinib. In contrast, progression due to CLL in 10 patients (11.9%) occurred later, diagnosed at a median 38 months on study. At progression, mutations in BTK (Cys481) and/or PLCG2 (within the autoinhibitory domain) were found in 9 patients (10.7%), in 8 of 10 patients with progressive CLL, and in 1 patient with prolymphocytic transformation. Applying high-sensitivity testing (detection limit ∼1 in 1000 cells) to stored samples, we detected mutations up to 15 months before manifestation of clinical progression (range, 2.9-15.4 months). In 5 patients (6.0%), multiple subclones carrying different mutations arose independently, leading to subclonal heterogeneity of resistant disease. For a seamless transition to alternative targeted agents, patients progressing with CLL were continued on ibrutinib for up to 3 months, with 19.8 months median survival from the time of progression. This trial was registered at www.clinicaltrials.gov as #NCT01500733.
引用
- Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017. PMID: 28049639. doi:10.1182/blood-2016-06-719294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。